NVAX vs TMO · P/E 2.5, rev $196.2M vs P/E 24, rev $23.00B
Novavax Inc (NVAX) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Latest reported TMO revenue for 2026-06-27 was $23.00B. Net income was $3.39B. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
NVAX currently screens at market cap $1.09B and trailing P/E 2.5. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the NVAX and TMO stock pages for the full models.
Not investment advice.